Form 4: Tandem Diabetes Care Executive Reports Stock Transactions
Insider Transaction Report
Tandem Diabetes Care Inc. executive Rick Carpenter reported a transaction involving restricted stock units on May 29, 2026.
Summary
- Rick Carpenter, EVP & Chief Technology Officer at Tandem Diabetes Care Inc., reported a transaction on May 29, 2026.
- The transaction involved 26,003 Restricted Stock Units (RSUs).
- These RSUs represent a contingent right to receive either one share of common stock or cash in lieu thereof.
- Vesting for these RSUs is scheduled as follows: one-third on May 29, 2027, and the remainder in eight equal quarterly installments thereafter.
- The filing also includes a Substitute Power of Attorney appointing Jerilyn Laskie as an attorney-in-fact for various individuals, including Rick Carpenter, to execute and file documents with the SEC.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine executive compensation and administrative actions (Power of Attorney) rather than significant financial performance or strategic shifts.
Positives
- The reporting of RSUs indicates a form of executive compensation tied to the company's performance and long-term value.
- The staggered vesting schedule encourages continued commitment from the executive.
Risks
- The value of the RSUs is subject to the future performance of Tandem Diabetes Care Inc.'s stock.
- The RSUs may be settled in cash at the company's discretion, introducing currency risk for the executive if stock is preferred.
Future Outlook
The RSUs are subject to vesting schedules extending into 2027, indicating a long-term incentive structure for the executive.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard for tracking insider transactions in the biotechnology and medical device sectors, reflecting compensation practices and executive commitment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Delegation | Shannon M. Hansen appointed as attorney-in-fact for multiple individuals, with the authority to execute and file SEC documents for Tandem Diabetes Care, Inc. Jerilyn Laskie is appointed as a substitute attorney-in-fact. | 05/20/2026 | Ensures compliance with SEC filing requirements even in the absence of direct signatory availability. |
Stakeholder Impact
- Shareholders: The transaction reflects executive compensation, which can impact dilution if settled in stock, but also signals executive retention and alignment with company performance.
- Employees: The RSU grant is part of the overall compensation structure for key executives.
- Management: Rick Carpenter's compensation is directly tied to the company's future performance through these RSUs.
Next Steps
- Vesting of RSUs on May 29, 2027, and subsequent quarterly installments.
- Potential settlement of RSUs in common stock or cash based on company discretion.
Key Dates
| Date | Description |
|---|---|
| 04/19/2022 | Date of Power of Attorney for Dick P. Allen and Elizabeth A. Gasser. |
| 04/20/2022 | Date of Power of Attorney for Peyton R. Howell, Rebecca B. Robertson, Christopher J. Twomey, and Leigh A. Vosseller. |
| 04/21/2022 | Date of Power of Attorney for Ricky A. Carpenter, Kathleen McGroddy-Goetz, Susan M. Morrison, and Rajwant S. Sodhi. |
| 05/20/2026 | Date of Substitute Power of Attorney executed by Shannon M. Hansen. |
| 05/29/2026 | Transaction Date for Restricted Stock Units and earliest transaction date reported. |
| 05/29/2027 | First vesting date for one-third of the reported RSUs. |
| 11/11/2025 | Date of Power of Attorney for Sandra W. Beaver. |
| 06/15/2022 | Date of Power of Attorney for Myoungil Cha and Joao Malagueira. |
| 06/21/2024 | Date of Power of Attorney for Jean-Claude Kyrillos. |
Keywords
Tandem Diabetes Care, TNDM, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Rick Carpenter, Power of Attorney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.